Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Amikacin for Inhalation in Recalcitrant NTM Lung Disease
NCT01315236Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Apr 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
A Phase 2 trial of amikacin liposome inhalation suspension in nontuberculous mycobacterial lung disease, sponsored by Insmed Incorporated. Started Apr 2012; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on NCT01315236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315236.